BARDA Opportunity: Endotyping for Host-Directed Therapeutics

Due Date: 29 July 2022 12:00pm ET Government Organization: BARDA Description: Office of Biomedical Advanced Research and Development Authority (BARDA) Division of Research, Innovation & Ventures (DRIVe) Special Instructions 018 Issuance for Easy Broad Agency Announcement (EZ-BAA) BAA-20-100-SOL-0002 Please find summaries a funding opportunity at BARDA DRIVe. If you have companies that you think are of interest, please send them directly to the HostTx team. Area of Interest #13: Endotyping for Host-Directed Therapeutics

Category: Opportunity

DoD Communities Of Interest: Biomedical ASBREM

Subject: BARDA Opportunity: Endotyping for Host-Directed Therapeutics

Due Date: 29 July 2022 12:00pm ET

Government Organization: BARDA

Description:

Office of Biomedical Advanced Research and Development Authority (BARDA) Division of Research, Innovation & Ventures (DRIVe)

Special Instructions 018 Issuance for Easy Broad Agency Announcement (EZ-BAA) BAA-20-100-SOL-0002

 

Below please find summaries a funding opportunity at BARDA DRIVe. If you have companies that you think are of interest, please send them directly to the HostTx team.

Area of Interest #13: Endotyping for Host-Directed Therapeutics

Technical POC:HostTx@hhs.gov

Overview: This funding opportunity is intended to support clinical development of host-directed therapeutics for infectious disease while simultaneously validating a means to sub-type patients that will benefit from the therapeutic in development. The mechanism to stratify patients should previously have been identified within a specific disease clinical phenotype (e.g., sepsis, ARDS, AKI, endotheliopathies) or across multiple etiologies (e.g. flu, COVID-19, pneumococcus) with a common clinical profile (e.g. lung dysfunction) that are likely to respond to a specific therapeutic. E

Out of Scope:

• Pathogen targeted products.

• Supportive care technologies that do not specifically improve clinical outcomes for patients.

• Exploratory research with no near-term translational application.

• Exploratory efforts to identify potential biomarkers /clinical characteristics to delineate patient sub-populations (i.e., biomarker discovery efforts).

• No IND established with FDA for therapeutic candidate in development

Questions:

Emil Runge

First Flight Venture Center

(404) 668-2136

Website: https://drive.hhs.gov/partner.html

Questions or assistance, contact:
North Carolina Defense Technology Transition Office (DEFTECH)

 

Dennis Lewis
lewisd@ncmbc.us
703-217-3127

Bob Burton
burtonr@ncmbc.us
910-824-9609

North Carolina Defense Technology Transition Office | PO Box 1748, Fayetteville, NC 28303